Further studies on the detection of early lung and breast carcinoma by T antigen.
We measured the cellular and humoral autoimmune response to carcinoma (CA)-associated T antigen in patients with the earliest clinical stages of lung (T1N0M0) and breast (Tis) CA. We used desialylated MN glycoprotein from healthy human erythrocytes in a single measurement of 1) delayed-type skin hypersensitivity response (DTHR-T) and 2) humoral anti-T response with a solid-phase immunoassay (SPIA-T). DTHR-T detected 19/20 lung CA and 10/12 ductal and 7/10 lobular breast CA patients. Sixteen of 18 stage T1N0M0 lung CA patients had a positive SPIA-T as did 7/8 patients with Tis breast CA. Two of 35 patients with benign lung and 11/144 with benign breast disease had a positive DTHR-T. None of 160 persons with either other non-CA diseases or healthy had a positive DTHR-T. Three of 68 such control subjects had a positive SPIA-T. The difference between CA patients and control populations is statistically highly significant.
D015295:Antigens, Tumor-Associated, Carbohydrate; D001943:Breast Neoplasms / Q000175:diagnosis / Q000276:immunology*; D002277:Carcinoma / Q000276:immunology*; D004187:Disaccharides / Q000032:analysis*; D005260:Female; D006801:Humans; D006968:Hypersensitivity, Delayed; D008175:Lung Neoplasms / Q000175:diagnosis / Q000276:immunology*
D015295:Antigens, Tumor-Associated, Carbohydrate; D004187:Disaccharides; C016467:Thomsen-Friedenreich antigen